Skip to main content
Premium Trial:

Request an Annual Quote

Biolidics, Sysmex Partner on Cancer Liquid Biopsy Development

NEW YORK — Biolidics said on Tuesday that it has partnered with Japanese diagnostics firm Sysmex on the development of a liquid biopsy-based cancer test for the Asian market.

The companies have been collaborating since 2016 on a liquid biopsy system that combines Biolidics' ClearCell FX1 automated label-free circulating tumor cell separation and enrichment platform with Sysmex's MI-FCM molecular imaging flow cytometer system.

Under the terms of their latest agreement, the companies will jointly develop a laboratory-developed test based on their respective technologies. Following clinical validation by Biolidics affiliate SAM Laboratory, Biolidics — formerly known as Clearbridge BioMedics — will commercialize the test in Asian markets outside of Japan.

Additional terms were not disclosed.

According to Singapore-based Biolidics, the ClearCell FX1 system — which recently received a Class I registration from the China National Medical Products Administration — is being evaluated in in laboratory-developed test collaborations by several organizations in China, including the Agen Medicine Laboratory Technology Company, TopGene Medical Laboratory Company, Genecast Biotechnology, and the Holistic Integrative Pharmacy Institute at Hangzhou Normal University.